Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy

Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis MIAMI BEACH, Fla., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of new and effective treatments for psychiatric and neurological disorders, today announced positive results from a preclinical proof of concept study of PAS002, its tolerizing vaccine program in multiple sclerosis (“MS”). Earlier this year, a [study]( in Nature, the world's leading science journal, showed that a molecule called GlialCAM found in the brain’s white matter is attacked in MS. GlialCAM shares a component of its protein structure that mimics an identical component of the Epstein Barr Virus (“EBV”) Nuclear Antigen-1, which plays a critical role in triggering MS. In this proof of concept study, relapsing paralysis was established in a mouse model of relapsing-remitting experimental autoimmune encephalomyelitis (“EAE”), the standard animal model of MS. In three groups, a proprietary DNA cassette was engineered to encode GlialCAM and injected to potentially block acute disease and its relapse. These DNA molecules were designed to protect against paralytic disease by tolerizing the immune system so it would not attack myelin in the brain and spinal cord. The engineered DNA molecule creates tolerance, working like an ‘inverse vaccine’, and was administered intra-muscularly at days 0, 3, 7, 10, and 14. The study had a standard duration of 32 days. The data showed that the engineered DNA plasmids provide a high level of efficacy in reducing disease severity and incidence of relapse when administered prophylactically in the EAE model, a widely used relapsing-remitting model of MS. Key findings from the study include: - treatment with a DNA tolerizing ‘inverse vaccine’ delayed the onset of paralysis when compared to vehicle (p<0.001); - a statistically significant reduction in disease severity, when compared to vehicle (p=0.002); - a statistically significant reduction in relapse severity, when compared to vehicle (p<0.001); - treatment with a DNA vaccine prevented disease in approximately 50% of the mice, when compared to vehicle (p=0.004). The study was conducted at Hooke Laboratories, an independent full-service Contract Research Organization with deep experience in the EAE animal model of MS. “The results of this study show that this technology has the potential to tolerize to GlialCAM, a myelin molecule that has molecular similarity to the Epstein Barr Virus that triggers MS,” stated Pasithea’s Chairman, National Academy of Sciences Professor Lawrence Steinman, a world recognized leading authority in MS. Prof. Steinman’s research led to the development of the drug Tysabri, which is approved to treat patients with MS and Crohn's disease. “Remarkably, the piece of GlialCAM protein shared between EBV and white matter in the brain is also found in the pox viruses, including monkeypox. Monkeypox is rarely associated with brain inflammation, and this new technology may prove useful as a treatment for brain inflammation caused in certain viral infections.” Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea, stated, "We’re thrilled with the strong preclinical efficacy data shown in this study. Although early stage, we believe these results demonstrate the promise and validity of our tolerizing approach, which is built on recent data on the biological mechanism linking infection with EBV with the development of MS. We have filed a provisional patent application and we will continue to rapidly pursue the PAS002 drug development program.” The Company plans to present data from this study, including histology data and plasma inflammatory markers, in future major international conferences, and also to submit full data for peer-review publication. About Multiple Sclerosis Multiple Sclerosis (“MS”) is a chronic and potentially disabling autoimmune disease, and the most common neurodegenerative disease of the central nervous system in young adults. The pathological hallmark of MS is the formation of demyelinating lesions in the brain and spinal cord, with the immune system attacking the myelin sheath that normally protects nerve fibers in the brain, spinal cord, and optic nerve. There are now 2.8 million people worldwide who have MS, and every five minutes, someone, somewhere in the world is diagnosed with this disorder. While there is no way to predict with any certainty how an individual’s disease will progress, four basic MS disease courses (also called types or phenotypes) have been defined: clinically isolated syndrome, relapsing remitting, secondary progressive and primary progressive. The most common affecting around 85 per cent of everyone diagnosed with MS is relapsing remitting MS (RRMS). It means that symptoms appear (a relapse), and then fade away, either partially or completely (remitting). ABOUT PAS002 PAS002 is an engineered DNA plasmid designed to tolerize the immune system to GlialCAM. About Pasithea Therapeutics Corp. Pasithea Therapeutics Corporation is a U.S. biotechnology company focused on the discovery, research and development of new and effective treatments for psychiatric and neurological disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders. Pasithea is also focused on addressing the needs of patients currently suffering with mental illness by providing access to IV ketamine infusions both in clinics and in-home settings. Forward Looking Statements This press release contains statements that constitute “forward-looking statements.” Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company’s filings with the SEC. Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law. Pasithea Therapeutics Corp. Company Contact Dr. Tiago Reis Marques Chief Executive Officer E: [tiago@pasithea.com]( Pasithea Therapeutics Corp. Investor Relations Lisa M. Wilson In-Site Communications, Inc. T: 212-452-2793 E: [lwilson@insitecony.com]( This website is wholly owned by tradigital marketing group, inc. (d/b/a “tradigital ir”). Our reports are advertorials and are for general information purposes only. never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our email list, as well as any social networking platforms we may use. please note well: tradigital ir and its employees are not registered investment advisors, broker-dealers, or member(s) of any association for other research providers in any jurisdiction whatsoever. release of liability: through use of this website, viewing or using you agree to hold tradigital ir, its operators, owners, and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. tradigital ir encourages readers and investors to supplement the information in these reports with independent research and other professional advice. all information on featured companies is provided by the companies profiled or is available from public sources and tradigital ir makes no representations, warranties, or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. none of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. instead, tradigital ir strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. tradigital ir’s full disclosure is to be read and fully understood before using tradigital ir's website, or joining tradigital ir's email or text list. From time to time, tradigital ir will disseminate information about a company via website, email, sms, and other points of media. by viewing tradigital ir's website and/or reading tradigital ir's email or text newsletter you are agreeing ----> . all potential percentage gains discussed in any communications are based on calculations from the low to the high of the day. We are engaged in the business of marketing and advertising companies for monetary compensation. in compliance with section 17(b) of the securities act we are disclosing that we have been compensated a fee pursuant to an agreement between tradigital and pasithea therapeutics corp. tradigital was hired for a period beginning january 2022 and ending march 2022 to publicly disseminate information about pasithea therapeutics corp. via website, email, and sms. We were paid three hundred ninety-four thousand usd via ach. Subsequently, we were paid four hundred ninety-nine thousand usd via ach to publicly disseminate information about pasithea therapeutics corp. via website, email, and sms. We own one hundred fifty thousand restricted common shares of pasithea therapeutics corp., which are eligible for sale on 03/18/2022. For the purpose of this disclaimer, we suggest that you assume we will sell all of our shares once the restriction is lifted on 03/18/2022. Readers are advised to review sec periodic reports: forms 10-q, 10k, form 8-k, insider reports, forms 3, 4, 5 schedule 13d. tradigital ir is compliant with the can-spam act of 2003. tradigital ir does not offer investment advice or analysis, and tradigital ir further urges you to consult your own independent tax, business, financial, and investment advisors. investing in micro-cap, small-cap, and growth securities is highly speculative and carries an extremely high degree of risk. it is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled.the private securities litigation reform act of 1995 provides investors a safe harbor in regard to forward-looking statements. any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events, or performance are not statements of historical fact may be forward-looking statements. forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quotes; may, could, or might occur. understand there is no guarantee past performance will be indicative of future results in preparing this publication, tradigital ir has relied upon information supplied by its clients, as well as its clients’ publicly available information and press releases which it believes to be reliable; however, such reliability can not be guaranteed. investors should not rely on the information contained on this website. rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, tradigital ir and its owners, affiliates, subsidiaries, officers, directors, representatives, and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. tradigital ir is not responsible for any claims made by the companies advertised herein, nor is tradigital ir responsible for any other promotional firm, its program, or its structure. tradigital ir is not affiliated with any exchange, electronic quotation system, the securities exchange commission, or finra. No longer want to receive these emails? [Unsubscribe](. TradigitalIR 12 E 49th Street, 11th Fl. New York, NY 10017 ‌